comparemela.com
  1. Home
  2. Live Updates
  3. Hlaa 02 - Breaking News

Hlaa 02 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OSE2101 Cancer Vaccine Yields Favorable OS vs SOC in HLA-A*02+ ICI-Resistant NSCLC

Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine.

France generalBenjamin besseInstitute gustave roussyCancer vaccineAtalante 1 trialHlaa 02

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.